The National Institutes of Health (NIH), the primary agency of the United States government responsible for biomedical and public health research, has come under intense scrutiny for its long-standing practice of directing taxpayer-funded grants to foreign research institutions. For decades, billions of dollars have been funneled to overseas laboratories to conduct experiments on animals, many of which involve high levels of physical distress, long-term confinement, and eventual euthanasia. This practice has sparked a legislative movement in Washington D.C., centered on the Cease Animal Research Grants Overseas (CARGO) Act, identified as H.R. 1085 and S. 1802. The proposed legislation seeks to prohibit the NIH from awarding grants to foreign entities for experiments involving animals, a move that supporters argue would save millions of taxpayer dollars and prevent the suffering of countless animals in facilities that often operate outside the direct oversight of U.S. animal welfare laws.
The scope of NIH international funding is vast. While the agency is headquartered in Bethesda, Maryland, its reach extends to nearly every continent. Proponents of international funding argue that global collaboration is essential for tackling pandemics and rare diseases. However, critics point to a series of controversial experiments that they claim provide little to no benefit to human medical advancement while consuming significant financial resources. The following analysis details the scale of these expenditures and the nature of the research conducted across various global regions.
The Legislative Context: The CARGO Act
The CARGO Act was introduced as a bipartisan effort to address what legislators describe as a lack of transparency and accountability in foreign animal research. Under current regulations, foreign laboratories receiving NIH funds are required to follow certain guidelines, but they are not subject to the same rigorous, unannounced inspections by the U.S. Department of Agriculture (USDA) that domestic laboratories must undergo.
The primary objective of H.R. 1085 and S. 1802 is to ensure that U.S. tax dollars are spent on research that adheres to American standards of oversight or, preferably, moves toward non-animal methodologies such as organ-on-a-chip technology, computer modeling, and human cell-based research. Analysts suggest that the passage of this act would represent one of the most significant shifts in federal research policy in the 21st century, potentially redirecting hundreds of millions of dollars toward domestic innovation.
Case Studies in NIH International Spending
Australia and the Pacific Region
Australia has been a major recipient of NIH funding for diverse animal-based studies. At the Walter and Eliza Hall Institute of Medical Research, experimenters received $1,546,428 between 2023 and 2025 to study toxoplasmosis. The research involved infecting animals with parasites that cause debilitating symptoms, including seizures and chronic diarrhea.
In another significant expenditure, Kinoxis Therapeutics was awarded $5,952,408 from 2019 to 2024 by the National Institute on Drug Abuse. This project utilized nearly 1,500 mice, over 300 rats, and 80 beagles. The animals were forced into opioid addiction to test molecules intended to treat withdrawal in humans. Additional Australian grants include $8,164,476 to the University of Sydney for tuberculosis experiments on monkeys and over $6 million to Vaxine Pty Ltd for influenza vaccine testing on primates.
The North American Corridor: Canada
Canadian institutions have secured substantial NIH contracts, often for highly invasive procedures. The University Health Network in Canada received $3,771,814 between 2014 and 2017 to induce strokes in rats and monkeys, leading to brain hemorrhages and rapid mortality. More recently, the same institution was granted $1,190,652 for 2024–2025 to perform lung transplants on pigs. These experiments, often categorized under "xenotransplantation" research, involve harvesting organs from "donor" pigs and surgically placing them into "recipients," who are later killed for tissue analysis.
At McGill University, a project funded by the National Institute on Deafness and Other Communication Disorders involved a $6,512,269 grant spanning from 2008 to 2025. In this study, experimenters reportedly cut the vocal cords of rabbits and used surgical instruments to exacerbate scarring and inflammation to study tissue injury.
South America and the Caribbean
The Caucaseco Scientific Research Center in Colombia represents one of the most controversial examples of international NIH funding. Between 2003 and 2023, the facility received $17,649,491 for malaria research. However, subsequent investigations revealed that monkeys and mice were kept in substandard conditions, leading to allegations of neglect and the eventual suspension of funding.
In Chile, the Universidad de Concepción received $2,380,836 over several decades to study alcohol abuse. The methodology included injecting alcohol into the abdominal cavities of mice and subjecting them to behavioral tests, such as tail-suspension, to measure their responses to intoxication. In the West Indies, the Ross University School of Veterinary Medicine in St. Kitts received over $100,000 to infect monkeys with typhus-causing bacteria.
European Research Hubs
European laboratories, despite having their own stringent regional regulations, continue to draw heavily from U.S. taxpayer funds. In Sweden, the Karolinska Institute has been a recurring partner for the NIH. Projects there include a $3,482,020 study involving spinal cord injuries in rabbits and a $2,051,061 grant to study the effects of aspartame on aging mice.
In the United Kingdom, Newcastle University received $1,819,429 for stroke experiments on monkeys, while University College London was granted nearly $800,000 for 2025 to develop abnormal proteins in the brains of mice to simulate neurodegenerative diseases. Other European grants include funding for brain electrode implantation in Finland and virus infection studies in Germany.
Research in Africa and Asia
NIH funding also extends to laboratories in Kenya, Nigeria, South Africa, and India. In Kenya, Kenyatta University received $629,696 to study schistosomiasis by infecting hamsters with parasites. In Nigeria, the Federal University of Technology received $393,634 to study the effects of high-protein and high-fat diets on the bladders of rats.
The Indian Institute of Science was awarded $241,992 for 2023–2024 to genetically modify mice to induce chronic gut inflammation and diarrhea. These studies are often justified by the prevalence of these specific diseases in the host countries, yet the "translatability" of these animal models to human clinical outcomes remains a point of heavy debate in the scientific community.
Financial and Scientific Implications
The financial data associated with these experiments paints a picture of a massive, decentralized research apparatus. When aggregating the costs of just the highlighted projects, the total exceeds $60 million. However, this is only a fraction of the total international spending by the NIH, which reaches hundreds of millions annually when accounting for all active grants.
From a scientific perspective, the reliance on animal models is increasingly questioned. Data from the National Center for Advancing Translational Sciences (NCATS) indicates that approximately 95% of new drugs that pass animal tests fail in human clinical trials because they are either unsafe or ineffective. This high failure rate suggests that the biological differences between species—such as the differences in how a mouse and a human metabolize a drug or respond to a virus—render many animal experiments obsolete.
Oversight and Accountability Challenges
One of the primary arguments for the CARGO Act is the difficulty of monitoring foreign facilities. While the NIH’s Office of Laboratory Animal Welfare (OLAW) requires foreign grantees to provide "Animal Welfare Assurances," these are often paper-based agreements. Unlike domestic labs, which are subject to the Animal Welfare Act (AWA) and regular inspections, foreign labs operate under their own national laws, which may be significantly more permissive or lack rigorous enforcement mechanisms.
The lack of direct oversight has led to instances where U.S. funds were used in facilities that did not meet basic sanitary or ethical standards. The case of the Colombian malaria clinic is often cited by policy analysts as a "worst-case scenario" of what happens when federal money is sent abroad without the ability to conduct hands-on inspections.
Conclusion and Future Outlook
The debate over NIH funding of foreign animal laboratories touches on the intersection of ethics, fiscal responsibility, and scientific efficacy. Supporters of the CARGO Act argue that by ending these grants, the U.S. can take a leadership role in promoting more humane and accurate research technologies. They contend that the "foreign loophole" allows for the continuation of experiments that would face significant public and regulatory pushback if conducted on American soil.
As the CARGO Act moves through the legislative process, it faces opposition from some sectors of the scientific community who fear that a total ban on foreign animal research grants could hinder international cooperation on global health threats. However, the growing body of evidence regarding the cruelty and scientific limitations of these experiments has created significant momentum for reform.
The ultimate impact of this legislation would be a fundamental restructuring of how the United States approaches global health research. By prioritizing domestic oversight and modern, non-animal research methods, the U.S. could potentially usher in a new era of medical discovery that is both more ethical and more effective for human health. For now, the records of the NIH stand as a testament to a decades-long policy of international animal experimentation—a policy that is now being challenged at the highest levels of government.
